about eiga
European Industrial Gases Association
The European Industrial Gases Association, EIGA, is a safety and technically oriented organisation representing the vast majority of European and a number of non-European companies producing and distributing industrial, medical and food gases.
Towards a European Industrial Deal
The Antwerp Declaration outlines 10 concrete actions, from integrating the EU Industrial Deal into the broader European Strategic Agenda 2024 – 2029 while complementing the EU Green Deal to fosterin...
Read more
Video
EIGA Winter Summit 2024 in Antwerp – A recap
"Enabling H2 together!" is our theme throughout 2024.
We kicked off the topic with our Winter Summit, which took place in January in Antwerp.
Over 180 people, expert and/or passionate about hydr...
See the video
News
Let’s enable H2 together
We hope you enjoyed the EIGA Winter Summit 2024!
The EIGA Team certainly did. We are taking this opportunity to warmly thank you for attending what we believe has been an outstanding event. Actuall...
Read more
documents
Latest Publications
Document
DOC 238 / 22 - Prevention of Plant Instrument and Utility Gas System Cross Contamination
This publication applies to HYCO plants and provides design and safeguards requirements of utility and instrument gas systems. It identifies the potential hazards resulting from the connections between gases, instrument gases, and the process.
DownloadTechnical Bulletin
TB 61 / 24 - Shortage Prevention Plan: Xenon
This publication describes the resulting risk priority level, based on the combination of impact to patient and likelihood of a drug shortage for the product, which is the same for all of our medicinal gases, ie. Risk Priority Level 3, with the residual risk of a drug shortage being generally accepted.
Therefore, it is proposed that there is no necessity to prepare additional Shortage Mitigation Plans as the risk of a drug shortage can be generally accepted.
EIGA also recommends that our medicinal products (medicinal gases) should be assessed as not required to be included in the “Union list of critical medicines” as the security in supply and prevention of shortages is assured.
DownloadTechnical Bulletin
TB 53 / 24 - Shortage Prevention Plan: Air-Medicinal and Air-Synthetic Medicinal
This publication describes the resulting risk priority level, based on the combination of impact to patient and likelihood of a drug shortage for the product, which is the same for all of our medicinal gases, ie. Risk Priority Level 3, with the residual risk of a drug shortage being generally accepted.
Therefore, it is proposed that there is no necessity to prepare additional Shortage Mitigation Plans as the risk of a drug shortage can be generally accepted.
EIGA also recommends that our medicinal products (medicinal gases) should be assessed as not required to be included in the “Union list of critical medicines” as the security in supply and prevention of shortages is assured.
Download